Theriva Biologics Reaches Target Patient Enrollment In VIRAGE Phase 2b Trial Of VCN-01 With Gemcitabine/Nab-Paclitaxel For Metastatic Pancreatic Cancer Treatment, Conducted Across 15 Sites In Spain And USA
Portfolio Pulse from Benzinga Newsdesk
Theriva Biologics has successfully reached its target patient enrollment for the VIRAGE Phase 2b trial of VCN-01 in combination with Gemcitabine/Nab-Paclitaxel for treating metastatic pancreatic cancer. The trial is being conducted across 15 sites in Spain and the USA.
September 23, 2024 | 12:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Theriva Biologics has reached its target patient enrollment for the VIRAGE Phase 2b trial of VCN-01, a significant milestone in its clinical development for metastatic pancreatic cancer treatment.
Reaching target patient enrollment is a critical milestone in clinical trials, indicating progress and potential for successful outcomes. This can positively influence investor sentiment and the stock price of Theriva Biologics (TOVX) in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90